OXFORD, England and SAN DIEGO, March 4 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.
Joel Centeno joins Enigma as VP Regulatory & Quality, US and will be responsible for obtaining appropriate regulatory approval for Enigma's rapid diagnostic instrument systems and products. Joel brings extensive executive experience in quality system design & implementation, new product development in molecular diagnostics and clinical trial expertise. Before joining the Enigma team, Joel served as Director, QA/RA at Hologic, Inc. where in addition to leading global quality and regulatory activities for the Molecular Diagnostic Division, he also obtained FDA approval on products including Cervista HPV and Inplex cystic fibrosis IVD tests. Joel received his B.S. in Materials Engineering and Metallurgy from the University of Florida in 1999.
About Enigma Diagnostics Limited
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
For more information visit www.enigmadiagnostics.com.
Enigma Diagnostics Limited